Evaluation of the Levels of Peripheral CD3+, CD4+, and CD8+ T Cells and IgG and IgM Antibodies in COVID-19 Patients at Different Stages of Infection

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection affects the stimulatory levels of cellular-mediated immunity, which plays an essential role in controlling SARS-CoV-2 infection. In fact, several studies have shown the association of lymphopenia with severe COVID-19 in patients. The aim of this study is to investigate the response of the immune system, including cell-mediated immunity and antibody production, during different stages of SARS-CoV-2 infection. Peripheral blood and serum samples were collected from patients with moderate infection, patients under medication (hospitalized), patients who had recovered, and healthy individuals (n = 80). Flow cytometry analysis was performed on peripheral blood samples to determine the cellular immunity profile of each patient. The data showed a significant reduction in the levels of CD3+, CD4+, and CD8+ T cells and CD45+ cells in the moderate and under-medication groups, suggesting lymphopenia in those patients. Also, enzyme-linked immunosorbent assay (ELISA) was conducted on the serum samples to measure the levels of antibodies, including IgM and IgG, in each patient. The results revealed a significant increase in the levels of IgM in the moderate infection and under-medication patients, thus indicating the production of IgM during the first week of infection. Furthermore, changes in the levels of IgG were significantly detected among recovered patients, indicating therefore a remarkable increase during the recovery stage of SARS-CoV-2 infection and thus a strong humoral-mediated immunity. In summary, the results of this study may help us to understand the main role of the cellular immune responses, including CD3+, CD4+, and CD8+ T cells, against SARS-CoV-2 infection. This understanding might support the development of SARS-CoV-2 treatments and vaccines in the near future. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China. This virus is a serious threat to people not only in China but also worldwide, where it has been detected in over 222 countries. It has been reported that ∼3.4% of SARS-CoV-2-infected patients have died. The significance of our study relies on the fact that an enzyme-linked immunosorbent assay and flow cytometry were used to measure the levels of antibodies and cellular immune response, respectively, from clinical samples of patients infected with SARS-CoV-2.

Abstract licence: CC BY

1. 13.
   Corrected

   Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study · 2020

2. 15.

   Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 · 2020

3. 20.

   Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 · 2020

4. 21.

   Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients · 2020

5. 22.

   Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) · 2020

6. 23.

   SARS-CoV-2 infection protects against rechallenge in rhesus macaques · 2020

7. 24.

   Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis · 2020

8. 25.

   Patterns of IgG and IgM antibody response in COVID-19 patients · 2020

9. 26.

   Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute respiratory distress syndrome · 2020

10. 27.

    Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques · 2020

11. 28.

    Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications · 2020

12. 33.
    Corrected

    Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals · 2020

13. 35.

    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity · 2020

14. 36.
    Corrected

    Impaired Cytotoxic CD8 + T Cell Response in Elderly COVID-19 Patients · 2020

15. 39.

    Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases · 2020

16. 40.

    Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection · 2021

24 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.